Table 1.
Dose-response efficacy of OlPC in the mouse L. major lesion cure model (MLL).
Figure 1.
In vivo efficacy of oral OlPC against L. major in comparison with other antileishmanial drugs.
BALB\c mice were infected with luciferase-labeled L. major promastigotes at the tail base. When lesions reached ∼50 mm2 oral treatment with OlPC (40 mg/kg/day), miltefosine (40 mg/kg/day), fluconazole (160 mg/kg/day), or vehicle control (PBS) was initiated for 21 consecutive days (Day 0–Day 20). Amphotericin B was given intraperitoneally (IP) at 25 mg/kg/day for 10 days (Day 0–Day 9). Parasitemia (A) was measured in every group by in vivo imaging (IVIS) on a weekly basis until Day 28 post treatment start and expressed as number of total photons emitted per second. Ulcer sizes (B) were measured weekly using a calibrated digital caliper. Mean ± SEM is shown. * amphotericin B P<0.05 compared to vehicle control. # amphotericin B and OlPC P<0.05 compared to vehicle control.
Figure 2.
Individual parasitemia and ulcer sizes on Day 19 post treatment start.
L. major infected BALB/c mice were treated with PBS vehicle control (oral), OlPC (oral, 40 mg/kg/day×21 days), miltefosine (oral, 40 mg/kg/day×21 days), fluconazole (oral, 160 mg/kg/day×21 days) and amphotericin B (IP, 25 mg/kg/day×10 days). Parasitemia (A and B) were measured on Day 19 using in vivo imaging technology (IVIS) and ulcer sizes were measured using a calibrated digital caliper (C). Means are shown as horizontal lines (B and C). * P<0.05 compared to vehicle control.
Table 2.
Weight variations in treatment groups during comparative efficacy study of OlPC in L. major infected BALB/c mice.
Table 3.
Sacrifices and found dead animals during comparative efficacy of OlPC in L. major infected BALB/c mice up to Day 35 post treatment start.